Allan Jonathan 4
4 · Stoke Therapeutics, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Stoke Therapeutics (STOK) General Counsel Allan Jonathan Sells Shares
What Happened Allan Jonathan, General Counsel and Corporate Secretary of Stoke Therapeutics (STOK), disposed of a total of 8,895 shares in open-market/private sales to satisfy tax withholding tied to the vesting/settlement of restricted stock units. The sales occurred 2026-03-17 and 2026-03-18, generating roughly $285,900 in proceeds across multiple transactions (individual reported lots: 2,476 @ $32.74 = $81,063; 1,791 @ $33.38 = $59,775; 4,222 @ $31.28 = $132,080; 334 @ $31.79 = $10,617; 72 @ $32.85 = $2,365). Transaction code: S (sale).
Key Details
- Dates of disposition: March 17–18, 2026; Form 4 filed March 19, 2026 (timely filing).
- Total shares sold: 8,895; total proceeds ≈ $285,900.
- Reported prices are weighted averages; filing footnotes provide price ranges for the multiple underlying trades.
- Footnote F1: these were issuer‑mandated sales to satisfy tax withholding obligations related to RSU vesting/settlement.
- Shares owned after the transactions are not provided in the excerpt of this filing.
Context These disposals were to cover tax withholding on vested RSUs (a routine administrative transaction) rather than an independent open‑market decision to reduce exposure. Such withholding sales are common and do not, by themselves, signal management sentiment about the company’s outlook.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-17$32.74/sh−2,476$81,063→ 35,255 total - Sale
Common Stock
[F1][F3]2026-03-17$33.38/sh−1,791$59,775→ 33,464 total - Sale
Common Stock
[F1][F4]2026-03-18$31.28/sh−4,222$132,080→ 29,242 total - Sale
Common Stock
[F1][F5]2026-03-18$31.79/sh−334$10,617→ 28,908 total - Sale
Common Stock
[F1]2026-03-18$32.85/sh−72$2,365→ 28,836 total
Footnotes (5)
- [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.